<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiplatelet effects of combination therapy with aspirin and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> were investigated in comparison with single aspirin or <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> therapy in 62 patients with <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The 14, 21 and 27 patients were given orally daily aspirin 300mg, <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> 200mg and aspirin 81mg with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> 100mg, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Various platelet function tests were performed before and a week after medication </plain></SENT>
<SENT sid="3" pm="."><plain>They included platelet aggregation (PA) to <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>), <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (AA) and platelet activating factor (PAF) with turbidimetry, plasma beta-thromboglobulin (beta TG), platelet factor 4(<z:chebi fb="0" ids="30203">PF4</z:chebi>), <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi>(<z:chebi fb="0" ids="28728">TXB2</z:chebi>) and 6keto-<z:chebi fb="0" ids="28852">prostaglandin-F1 alpha</z:chebi>(6keto <z:chebi fb="0" ids="28852">PGF1 alpha</z:chebi>) with radioimmunoassay, <z:mp ids='MP_0001914'>bleeding</z:mp> time with Simplate device, and platelet survival and lysis with <z:chebi fb="1" ids="30430">Indium</z:chebi>-111-tropolone-labelled platelets </plain></SENT>
<SENT sid="4" pm="."><plain>Aspirin inhibited PA to <z:chebi fb="13" ids="16761">ADP</z:chebi> and AA but not to PAF, while <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> inhibited PA to <z:chebi fb="13" ids="16761">ADP</z:chebi> and PAF but not to AA </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, aspirin with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> inhibited PA to <z:hpo ids='HP_0000001'>all</z:hpo> of these <z:chebi fb="4" ids="48705">agonists</z:chebi> despite their smaller doses used </plain></SENT>
<SENT sid="6" pm="."><plain>Aspirin reduced plasma <z:chebi fb="0" ids="28728">TXB2</z:chebi> but not beta TG or <z:chebi fb="0" ids="30203">PF4</z:chebi>, while <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> reduced beta TG and <z:chebi fb="0" ids="30203">PF4</z:chebi> but not <z:chebi fb="0" ids="28728">TXB2</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>On the contrary, aspirin with <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> reduced <z:chebi fb="0" ids="28728">TXB2</z:chebi> as well as beta TG and <z:chebi fb="0" ids="30203">PF4 </z:chebi></plain></SENT>
<SENT sid="8" pm="."><plain>6keto <z:chebi fb="0" ids="28852">PGF1 alpha</z:chebi> tended to be reduced by aspirin 300mg alone but not by <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> with or without aspirin 81mg </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time was significantly prolonged by aspirin or <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> alone, although most prolongation was produced by combination of aspirin and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Platelet survival and lysis remained unaltered in 4 patients treated with aspirin or <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> alone, whereas platelet survival was prolonged and platelet lysis was reduced in 4 patients treated with both aspirin and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>